| N | 5-Year DDFS (%) (95 % CI) | HR (95 % CI) | p-valuea |
---|---|---|---|---|
Age | ||||
  < 35 | 30 | 82.6 [68.2–100] | 1 |  |
  ≥ 35 | 726 | 93.3 [91.2–95.4] | 0.5 [0.2–1.3] | 0.1223 |
SBR Grade | ||||
 1–2 | 462 | 96 [94–98] | 1 |  |
 3 | 285 | 87.4 [82.9–92.1] | 2.8 [1.6–4.9] | 0.0002 |
Pathological tumor size | ||||
 pT1 | 391 | 93.6 [90.9–96.5] | 1 |  |
 pT2 | 320 | 92.3 [88.9–95.7] | 1.2 [0.7–2] |  |
 pT3-T4 | 36 | 88.2 [78–99.8] | 1.6 [0.6–4.7] | 0.6395 |
PVI | ||||
 No | 558 | 94.2 [92–96.5] | 1 |  |
 Yes | 178 | 88.8 [83.5–94.5] | 2.2 [1.3–4] | 0.0042 |
Hormone receptors | ||||
 Negative | 208 | 88 [83–93.4] | 1 |  |
 Positive | 526 | 94.7 [92.5–96.9] | 0.6 [0.3–1] | 0.049 |
HER2 | ||||
 Negative | 507 | 93.2 [90.5–95.9] | 1 |  |
 Positive | 96 | 95.7 [91–100] | 0.9 [0.3–2.2] | 0.7719 |
IHC subtypes | ||||
 Luminal A | 289 | 96.8 [94.5–99.2] | 1 |  |
 Luminal B/HER2-negative | 82 | 85.5 [76.3–95.8] | 4.6 [1.8–11.7] |  |
 Luminal B/HER2-positive | 58 | 100 [100–100] | 1.2 [0.2–5.5] |  |
 HER2 | 37 | 89 [77.6–100] | 2.9 [0.8–11.1] |  |
 Triple-negative | 127 | 89 [82.5–96] | 3.3 [1.3–8.2] | 0.0059 |